Etienne Thoreau

This inventor holds 19 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 11 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Galderma Research & Development, Centre International De Recherches Dermatologiques Galderma. Active years: 1999-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Etienne Thoreau. Retrieved from https://idiyas.com/inventor/etienne-thoreau

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 19 (Patent Applications = 1)

% Patents Active = 47.4

CIPO Patents = 2 (Patent Applications = 5)

EPO Patents = 11 (Patent Applications = 9)

Average Co-Inventor Count = 3.5

ph-index = 2

Forward Citations = 20(Granted Patents)

Location History:

Vence, FR (1999)
Saint-Vallier-de-Thier, FR (2009)
Saint Vallier De Thiey, FR (1999 - 2023)

Company Filing History:

17 out of 222

Galderma Research & Development

patents

2 out of 44

Centre International De Recherches Dermatologiques Galderma

patents

Years Active: 1999-2023

Loading Chart...

Areas of Expertise:

mTOR Inhibitors

Indazole Derivatives

Sulfonamide Compounds

PPAR Modulation

Retinoid Agonists

Biphenyl Compounds

Vitamin D Analogues

Heterocyclic Compounds

Pharmaceutical Compositions

Cosmetic Compositions

Polycyclic Compounds

Biaromatic Compounds

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11731973 - Substituted pyrazolo[3,4-d]pyrimidines as mTOR inhibitors (2023-08-22),

2. 11518767 - MTOR inhibitor compounds (2022-12-06),

3. 10752617 - Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (T)) (2020-08-25),

4. 10618890 - Benzimidazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (T)) (2020-04-14),

5. 10550110 - Tetrahydroquinoline sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (t)) (2020-02-04),

6. 10457637 - Benzenesulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (RORγ(T)) (2019-10-29),

7. 10246440 - Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR γ (T)) (2019-04-02),

8. 10246422 - Heterocyclic compounds and use thereof in medicine and in cosmetics (2019-04-02),

9. 8362082 - Biphenyl compound selective agonists of gamma RAR receptors (2013-01-29),

10. 8106235 - Biphenyl compound selective agonists of gamma RAR receptors (2012-01-31),

11. 8049034 - Biphenyl compound selective agonists of gamma RAR receptors (2011-11-01),

12. 8022079 - Methods of modulating PPAR gamma-type receptors (2011-09-20),

13. 7973063 - Methods for activating PPAR gamma-type receptors (2011-07-05),

14. 7968560 - Compounds that modulate PPARγ-type receptors and cosmetic/pharmaceutical compositions comprising said compounds (2011-06-28),

15. 7626054 - Biaromatic compounds which activate PPARγ-type receptors and cosmetic/pharmaceutical compositions comprised thereof (2009-12-01),

Title: Etienne Thoreau: Innovator in mTOR Inhibitors

Introduction

Etienne Thoreau, an accomplished inventor based in Saint Vallier de Thiey, France, has made significant contributions to the field of pharmaceuticals, particularly in the development of mTOR inhibitors. With a total of 19 patents to his name, Thoreau's work continues to impact drug composition and therapeutic methods.

Latest Patents

Among Thoreau's latest inventions are two notable patents focusing on substituted pyrazolo[3,4-d]pyrimidines as mTOR inhibitors. The first patent describes novel mTOR inhibitor compounds, represented by a specific formula, along with their pharmaceutically acceptable salts, methods for their production, and applications in therapeutic compositions. The second patent also delves into mTOR inhibitor compounds characterized by a general formula, detailing the methods for their synthesis and their potential as pharmacological agents.

Career Highlights

Throughout his career, Thoreau has worked at reputable organizations such as Galderma Research & Development and International Center for Dermatological Research Galderma. His contributions to these institutions have been instrumental in the advancement of dermatological treatments and therapies.

Collaborations

Thoreau has collaborated with esteemed colleagues, including Laurence Clary and Gilles Ouvry. These partnerships have fostered innovation and propelled research initiatives that align with his specialization in mTOR inhibition and related fields.

Conclusion

Etienne Thoreau exemplifies the innovative spirit of modern inventors, with his significant portfolio of patents reflecting his dedication to advancing pharmaceutical science. His work on mTOR inhibitors showcases the potential of targeted therapies in medicine, paving the way for future developments in this critical area of research.

Profile summary based on public USPTO records.